Louisiana State Employees Retirement System Makes New $2.82 Million Investment in DexCom, Inc. $DXCM

Louisiana State Employees Retirement System purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the first quarter, Holdings Channel reports. The institutional investor purchased 44,900 shares of the medical device company’s stock, valued at approximately $2,820,000.

A number of other institutional investors have also bought and sold shares of the company. Reflection Asset Management bought a new stake in DexCom during the 4th quarter valued at $25,000. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares in the last quarter. MCF Advisors LLC purchased a new position in DexCom in the fourth quarter worth $32,000. ORG Partners LLC grew its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares during the period. Finally, DV Equities LLC bought a new position in shares of DexCom during the 4th quarter valued at approximately $36,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on DXCM. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research report on Friday, May 1st. Benchmark restated a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Price Performance

Shares of DexCom stock opened at $70.14 on Monday. The company has a 50-day moving average of $67.65 and a 200 day moving average of $68.09. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a market cap of $27.06 billion, a price-to-earnings ratio of 29.97, a PEG ratio of 1.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business posted $0.32 EPS. DexCom’s revenue was up 15.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 46,694 shares of company stock worth $3,343,977. 0.28% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.